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ABSTRACT Ceftolozane-tazobactam (C/T) is a novel beta-lactam–beta-lactamase inhibi-
tor combination antibiotic approved by the U.S. Food and Drug Administration in 2014
for the treatment of complicated intra-abdominal infections (in combination with metro-
nidazole) and complicated urinary tract infections. In this study, we evaluated the perfor-
mance of the C/T Etest, a gradient diffusion method. C/T Etest was compared to broth
microdilution (BMD) for 51 Enterobacteriaceae challenge isolates and 39 Pseudomonas
aeruginosa challenge isolates at three clinical sites. Essential agreement (EA) between the
methods ranged from 47 to 49/51 (92.2 to 96.1%) for the Enterobacteriaceae, and cate-
gorical agreement (CA) ranged from 49 to 51/51 (96.1 to 100.0%). EA and CA for P.
aeruginosa were 100% at all sites. The C/T Etest was also compared to BMD for suscepti-
bility testing on 966 clinical isolates (793 Enterobacteriaceae, including 167 Klebsiella
pneumoniae and 159 Escherichia coli isolates, in addition to 173 P. aeruginosa isolates)
collected at four clinical sites. EA between Etest and BMD was 96.9% for Enterobacteria-
ceae isolates and 98.8% for P. aeruginosa isolates. Within the Enterobacteriaceae, isolates
from each species examined had 96% CA. For the clinical isolates, no very major errors
were identiﬁed but two major errors were found (one for K. pneumoniae and one for
Providencia rettgeri). By BMD, 47.0% of Enterobacteriaceae and 46.2% of P. aeruginosa
challenge strains were nonsusceptible to C/T by CLSI breakpoint criteria; 8.2% of clinical
Enterobacteriaceae isolates and 12.1% of clinical P. aeruginosa isolates were nonsuscep-
tible to C/T by CLSI breakpoint criteria. In conclusion, Etest is accurate and reproducible
for C/T susceptibility testing of Enterobacteriaceae and P. aeruginosa.
KEYWORDS antimicrobial susceptibility testing, Etest, gradient diffusion method,
Pseudomonas aeruginosa, Enterobacteriaceae, ceftolozane-tazobactam
Ceftolozane-tazobactam (C/T) is a new beta-lactam–beta-lactamase inhibitor combi-nation agent that combines a novel oxyimino-cephalosporin (ceftolozane) with an
established beta-lactamase inhibitor (tazobactam). C/T was approved by the U.S. Food and
Drug Administration in 2014 for the treatment of complicated intra-abdominal infections
(cIAI, in combination withmetronidazole) and complicated urinary tract infections (cUTI) (1).
In clinical trials, C/T demonstrated noninferiority to meropenem when used in combination
with metronidazole for the treatment of cIAIs (2, 3). Additionally, C/T was noninferior to
levoﬂoxacin for the treatment of cUTIs, including pyelonephritis (4), which was mainly
attributable to high rates of levoﬂoxacin-resistant isolates among cUTI-causing bacteria (5,
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6). In vitro, C/T inhibits the growth of a high percentage of bacterial isolates from the
medically important Enterobacteriaceae family and Pseudomonas aeruginosa, outperform-
ing several current ﬁrst-line antibiotics for the treatment of multidrug-resistant (MDR)
organisms (3, 7–14). Nevertheless, resistance to C/T has been observed, emphasizing the
need for C/T susceptibility testing in clinical microbiology laboratories (15–17). Here we
report a multicenter evaluation of a C/T Etest (bioMérieux, Durham, NC) which was recently
cleared by the U.S. FDA for in vitro diagnostic use (18).
MATERIALS AND METHODS
Ethics statement. Prior to study initiation, each study site acquired approval or waiver from their
respective institutional review board.
Quality control. The following isolates were used for quality control (QC) of the C/T Etest and broth
microdilution (BMD) each day of testing: Escherichia coli ATCC 25922, Escherichia coli ATCC 35218,
Pseudomonas aeruginosa ATCC 27853, Klebsiella pneumoniae ATCC 700603, and Staphylococcus aureus
ATCC 29213 (BMD only), using Clinical and Laboratory Standards Institute (CLSI) QC ranges for these
strains. Quality control results were within acceptable limits for 99% of quality control tests performed
on each quality control organism, and quality control was veriﬁed to be within normal limits on every day
that comparative analysis was performed (i.e., challenge and clinical studies). Quality control testing was
performed a minimum of 20 times at each site.
Setting. Testing was performed at the Clinical Microbiology Institute (CMI; Portland, OR), the
University of California-Los Angeles (UCLA; Los Angeles, CA) Health System, the University of Indiana
(WU; Indianapolis, IN), Washington University in St. Louis School of Medicine (WU; St. Louis, MO), and
bioMérieux St. Louis Clinical Affairs (St. Louis, MO).
Clinical isolates and C/T susceptibility testing. A combination of fresh and previously frozen
clinical isolates was evaluated in this study: Enterobacteriaceae (422/793 fresh; 371/793 frozen) and P.
aeruginosa (109/173 fresh; 64/173 frozen). Isolates were recovered and identiﬁed from patient specimens
using standard-of-care culture media and procedures at each study site. For C/T susceptibility testing
using the Etest, Mueller-Hinton agar II plates (Remel Inc., San Diego, CA) were inoculated with a sterile
cotton swab moistened with a 0.5 McFarland suspension and the Etest strip was placed on the plate with
an applicator or forceps. Plates were incubated in ambient air at 35  2°C and read at 16 to 20 h
postinoculation. For BMD, 0.01 ml of a 0.5 McFarland solution that had been diluted 1:300 was inoculated
into 95 wells of a 96-well plate using a 96-well-plate inoculator. BMD plates containing 0.1 ml of diluted
C/T solutions were prepared by bioMérieux according to processes described in CLSI documents M100
and M7 (19, 20) using Becton Dickinson Mueller-Hinton medium and stored at 70°C until use. All BMD
plates were read following 16 to 20 h of incubation in ambient air at 35  2°C. Directions for reading the
C/T Etest (i.e., the Etest reading guide and the supplemental package insert) were provided to sites. These
materials included instruction on interpreting hazes (which were included as growth with the exception
of swarming by Proteus species) and colonies within the zone (which were counted as true growth).
Magnifying lenses were also supplied to each site, but magniﬁcation was not required for reading of Etest
results. An example of Etest results for the species used in this study can be found in Fig. 1.
Reproducibility and challenge testing. Reproducibility testing was performed using a set of 25
on-scale strains (i.e., strains that had expected MICs falling within the measurable range of the Etest
device); all strains were tested at three clinical sites using the Etest exclusively. An inoculum density
FIG 1 Interpretation of Etest results. C/T Etest strips were placed onto Mueller-Hinton agar plates that had been inoculated using a sterile
cotton swab moistened with a 0.5 McFarland suspension. Plates were then read after incubation in ambient air at 35  2°C for 16 to 20
h. The MIC result was read where the zone of inhibition ellipse intersected the Etest strip; if the ellipse intersected between two MIC values,
the higher of the two values was reported. Hazy growth and colonies within the ellipse were counted as true growth.
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check was performed on all isolates. Challenge testing was performed at three clinical sites using 90
frozen stock organisms provided by bioMérieux. All challenge isolates were tested using Etest and BMD.
To derive the MIC for BMD in the challenge study, this trial used a voted reference result as the basis for
comparison. The voted reference was derived by comparing the BMD results from all three sites for each
isolate. The voted reference result was either a consensus result, the best two of three, or a modal value.
In situations where all three reference results were the same, the consensus result was used.
Interpretation of results and data analysis. Results from all isolates tested for C/T susceptibility
using the Etest and BMD methods were included in the analysis. Essential agreement (EA) was deﬁned
as agreement between the two methods 1 doubling dilution and was calculated by the Biomath team
at bioMérieux. Etest results were rounded up to the nearest dilution that was performed for BMD for this
calculation. Categorical agreement (CA) between the Etest and BMD, as well as very major, major, and
minor error evaluation, was determined using CLSI breakpoint criteria unless otherwise speciﬁed.
RESULTS
Reproducibility of C/T Etest. We used isolates of Enterobacter cloacae (n  1),
Escherichia coli (n  7), Klebsiella oxytoca (n  3), Klebsiella pneumoniae (n  5), and
Pseudomonas aeruginosa (n  9) to evaluate the reproducibility of the Etest at three
sites: the Clinical Microbiology Institute (CMI; Portland, OR), the University of California-
Los Angeles (UCLA; Los Angeles, CA) Health System, and Washington University in St.
Louis School of Medicine (WU). The MICs of C/T required to inhibit growth of each
isolate were compared across sites (Table 1), showing that 73/75 (97.3%) isolates tested
fell within 1 doubling dilution of the mode (or the median, if no mode existed).
C/T Etest challenge study. To examine the accuracy of the Etest, we compared
MICs derived by C/T Etest to MICs derived by BMD for 51 Enterobacteriaceae and 39 P.
aeruginosa strains at CMI, UCLA, and WU (see Table S1 in the supplemental material for
details on each isolate). Among the Enterobacteriaceae isolates evaluated, 23/51 (45%)
were resistant to C/T by BMD using the CLSI breakpoints (susceptible [S], 2/4 g/ml;
TABLE 1 Reproducibility of C/T Etest
Organism
MIC (g/ml) DDa from the median/mode
Site A Site B Site C Mode/median Off-scale 2 1 0 1 2 Off-scale
E. cloacae 16 16 32 16 2 1
E. coli 1 1 2 1 2 1
1 2 8 2b 1 1 1
0.5 0.5 1 0.5 2 1
0.5 0.5 1 0.5 2 1
0.125 0.125 0.125 0.125 3
2 2 2 2 3
0.125 0.125 0.125 0.125 3
K. oxytoca 4 2 4 4 1 2
0.5 0.5 0.5 0.5 3
1 0.5 2 1b 1 1 1
K. pneumoniae 64 256 128 128b 1 1 1
1 2 1 1 2 1
32 256 64 64b 1 1 1
2 1 1 1 2 1
0.5 0.25 0.25 0.25 2 1
P. aeruginosa 128 128 256 128 2 1
64 64 128 64 2 1
1 1 2 1 2 1
0.5 0.5 1 0.5 2 1
2 2 4 2 2 1
1 1 1 1 3
1 1 1 1 3
0.5 0.5 0.5 0.5 3
0.5 0.5 0.5 0.5 3
Total 0 0 5 54 14 2 0
aDD, double dilution.
bMedian value.
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intermediate [I], 4/4 g/ml; resistant [R], 8/4 g/ml), while 27/51 (53%) were suscep-
tible and 1/51 was intermediate (Table 2). Similarly, 18/39 (46%) P. aeruginosa strains
evaluated were resistant and 21/39 (54%) were susceptible by BMD using CLSI break-
point criteria (S, 4/4 g/ml; I, 8/4 g/ml; R, 16/4 g/ml). Essential agreement (EA)
between the C/T Etest and BMD methods ranged from 47/51 (92.2%) to 49/51 (96.1%)
for the Enterobacteriaceae species; categorical agreement (CA) ranged from 49/51 (96.1)
to 51/51 (100%), with 1 very major error, 1 major error, and 2 minor errors identiﬁed.
EA and CA for P. aeruginosa were 100% at all sites.
Clinical performance of C/T Etest. We examined the performance of the C/T Etest
at ﬁve sites: CMI, UCLA, WU, Indiana University School of Medicine (Indianapolis, IN),
and bioMérieux St. Louis Clinical Affairs (St. Louis, MO). A combined total of 966 clinical
isolates were evaluated across the ﬁve study sites, including 793 strains of Enterobac-
teriaceae and 173 isolates of P. aeruginosa. The majority of Enterobacteriaceae (428/793
[54.0%]) were isolated from urine, while respiratory specimens were the most common
source of P. aeruginosa isolates (52/173 [30.1%]) (see Table S2 for the specimen type
from which each isolate was recovered and the corresponding MIC of each isolate). Per
CLSI breakpoints for the Enterobacteriaceae, 56/793 (7.1%) of patient isolates were
resistant to C/T by BMD, 728/793 (91.8%) were susceptible, and 9/793 (1.1%) had MICs
that fell within the intermediate category (Table 3). The species with the highest
percentage of resistant isolates were E. cloacae (8/53 [15.1%]) and K. oxytoca (7/58
[12.1%]). For P. aeruginosa, 17/173 (9.8%) of patient isolates were resistant by BMD
using CLSI breakpoints, while 152/173 (87.9%) of isolates were susceptible and 4/173
(2.3%) were of intermediate susceptibility. EA between BMD and Etest was 768/793
(98.5%) for Enterobacteriaceae collectively (Fig. 2A), with the EA for each species within
the Enterobacteriaceae ranging from 93.4% (K. pneumoniae) to 100%. CA for Enterobac-
teriaceae isolates collectively was 781/793 (98.5%), with the CA for each species within
the Enterobacteriaceae ranging from 96.2% (E. cloacae) to 100%. For P. aeruginosa, EA
and CA of the C/T Etest versus BMD were 171/173 (98.8%) and 172/173 (99.4%),
respectively (Table 3; Fig. 2B). No very major errors were identiﬁed in our clinical study.
However, two major errors were found: one K. pneumoniae isolate with an Etest MIC of
64 g/ml and a BMD MIC of 0.5 g/ml and one P. rettgeri isolate with an Etest MIC of
8 g/ml and a BMD MIC of 2 g/ml. Eleven minor errors were also identiﬁed: 10 from
Enterobacteriaceae isolates and 1 from a P. aeruginosa isolate, with no obvious bias
toward one pattern of minor error.
We also analyzed the categorical interpretation of our clinical data using European
Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, which are
more conservative than CLSI breakpoints for Enterobacteriaceae and do not include an
intermediate category (for Enterobacteriaceae, S, 1/4 g/ml, and R, 1/4 g/ml; for P.
aeruginosa, S, 4/4 g/ml, and R, 4/4 g/ml). Using EUCAST breakpoints, CA was
higher for both Enterobacteriaceae (785/793 [99.0%]) and P. aeruginosa (173/173
[100%]) than CLSI breakpoints. However, more very major (n  3) and major errors
(n  5) were found when using EUCAST criteria (Table 3).





result by BMD Performance, no. (%)
S I R EA CA VMEs MEs mEs
Enterobacteriaceae A 51 27 1 23 47 (92.2) 51 (100) 0 (0) 0 (0) 0 (0)
B 51 27 1 23 49 (96.1) 49 (96.1) 0 (0) 1 (3.7) 1 (2.0)
C 51 27 1 23 48 (94.1) 49 (96.1) 1 (4.3) 0 (0) 1 (2.0)
P. aeruginosa A 39 21 0 18 39 (100) 39 (100) 0 (0) 0 (0) 0 (0)
B 39 21 0 18 39 (100) 39 (100) 0 (0) 0 (0) 0 (0)
C 39 21 0 18 39 (100) 39 (100) 0 (0) 0 (0) 0 (0)
aR, resistant; I, intermediate; S, susceptible; EA, essential agreement (MIC  1 doubling dilution); CA, categorical agreement; VMEs, very major errors; MEs, major errors;
mEs, minor errors.
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C/T is a novel beta-lactam–beta-lactamase inhibitor combination that was devel-
oped for the treatment of infections with multidrug-resistant Gram-negative bacteria.
In this study, C/T susceptibility testing was performed on a large number of Gram-
negative bacterial isolates at multiple study sites across a large geographic distribution
in the continental United States. We found that the MIC values derived by the Etest for
C/T correlated well with MIC values obtained by BMD for both Enterobacteriaceae and
P. aeruginosa, exceeding the 90% threshold of EA required by the FDA. Additionally,
we identiﬁed very few categorical and very major errors using CLSI breakpoint criteria
for Enterobacteriaceae and P. aeruginosa.
Despite growing interest in the use of C/T by physicians (21), only a limited number
of studies have evaluated the performance of alternatives to BMD for C/T susceptibility
testing. Among these studies, a considerable range of performance has been observed
for a variety of C/T susceptibility testing devices. For example, a research-use-only
(RUO) version of the Etest performed poorly compared to BMD for susceptibility testing
FIG 2 Correlation of C/T MICs from Etest and BMD. Clinical isolates identiﬁed as Enterobacteriaceae
(n  793) (A) or P. aeruginosa (B) (n  173) were subjected to C/T susceptibility testing by Etest and
BMD. The numbers of isolates with MICs corresponding to each test method are shown, with darker
squares corresponding to MIC values displayed by a larger number of isolates. CLSI breakpoints are
shown as dark solid lines, with their respective interpretation for each method shown to the left and
top of the plot.
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of a small number of meropenem-nonsusceptible P. aeruginosa isolates in Michigan
(22), but these data were later questioned when a follow-up to this study suggested
favorable performance characteristics for the C/T Etest (96% EA and CA) (23). Al-
though our study did not produce any very major errors in the clinical isolate portion
of the study, one very major error was identiﬁed in the challenge set study. Interest-
ingly, the isolate for which this error occurred had Etest and BMD results that were
internally consistent at each site; however, this isolate had MICs in the susceptible
range at one site but MICs that were resistant at the two other sites. Therefore, when
the voted BMD reference value was generated, this created a very major error for the
one site at which the isolate tested as susceptible. Given the consistency of test results
for this isolate within each site, it appears that this error was not due to a failure of the
test device but rather an artifact of the data analysis in combination with the possibility
of the loss of a resistance plasmid.
Other devices that use gradient diffusion (e.g., Lioﬁlchem MIC test strip) for C/T
testing have been shown to have unacceptably high error rates (23). These discrepan-
cies could reﬂect the fact that interpretation of MIC results from gradient diffusion
devices can be more subjective than BMD results. In addition, the population distribu-
tion of many Gram-negative species falls near the breakpoint for this antimicrobial
agent, which can be challenging for accurate categorical interpretation. However,
various degrees of performance have also been reported for disk diffusion assays for
C/T disks (23–25). Despite these limitations, in most clinical laboratory settings, C/T
susceptibility testing options like gradient diffusion that are more accessible than BMD
are critically needed because approximately 10% of infections for which C/T therapy is
indicated are caused by a C/T-resistant organism and therefore susceptibility testing is
needed to optimize therapy and antimicrobial stewardship (6, 7, 9–17, 24, 26, 27).
Indeed, C/T resistance and treatment failures have already been described and appear
to be acquired/mediated via a variety of mechanisms, emphasizing the need for widely
accessible phenotypic C/T susceptibility testing (8, 11, 24, 28–30).
This study has limitations, including the small number of isolates for some of the
speciﬁc species evaluated and the lack of resistant isolates for some species tested. The
strengths of this study include reference BMD as a reference method, standardization
of preparation of the BMD panels, the large number of isolates evaluated, and the
multicenter nature of the study.
In conclusion, testing a large number of clinical strains from different geographic
regions within the United States, we found that the bioMérieux C/T Etest is a repro-
ducible and accurate method for C/T susceptibility testing of Enterobacteriaceae and P.
aeruginosa.
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